GLP-1 Eligibility Checklist: Who Actually Qualifies and What Doctors Screen For

Most people ask one simple question first: “Do I qualify for a GLP-1?” In clinical practice, the answer is rarely a one-line yes or no. Eligibility sits at the intersection of body-weight criteria, cardiometabolic risk, medication interactions, symptom burden, life stage (including pregnancy plans), and ability to follow through on monitoring.

That complexity is not a barrier; it is a safety feature. The best outcomes usually happen when eligibility is evaluated in a structured way before the first prescription. This guide gives you that structure.

Use it to prepare for your first visit, bring cleaner data, and reduce avoidable delays. It is educational—not individualized medical advice—and should be used alongside a licensed clinician’s assessment.

Compliance note: Criteria and coverage vary by diagnosis, product labeling, insurer policies, and jurisdiction. Never start, stop, or adjust prescription medication without clinician guidance.

Why “eligible” and “appropriate right now” are different decisions

A person can meet broad BMI-based criteria and still need short-term stabilization before initiation. Another person may have borderline BMI but significant metabolic disease and high clinical benefit potential. This is why high-quality clinicians assess both:

1. Eligibility threshold (whether treatment can be reasonably considered), and
2. Readiness and timing (whether now is the safest time to start).

Common reasons to delay rather than deny include severe uncontrolled GI symptoms, active eating disorder symptoms, unstable psychiatric status, incomplete medication reconciliation, or pending fertility plans.

Delay is often protective—not punitive.

A practical 7-domain GLP-1 eligibility framework

Use these domains as your visit prep checklist.

Domain 1: Anthropometrics and weight-related health risk

Bring objective measurements:

• Current height, weight, and BMI
• 6–12 month weight trend (not just one number)
• Waist circumference if available
• Blood pressure trend (home logs are useful)

Why this matters:

• BMI alone does not capture body composition or risk distribution.
• Recent weight trajectory helps distinguish stable obesity from rapidly changing patterns.
• Waist trend can support metabolic risk assessment when scale data are noisy.

Domain 2: Metabolic and organ-system baseline

Bring recent labs when possible (or ask what should be repeated):

• A1c and/or fasting glucose
• Lipid panel
• CMP (including liver enzymes and renal markers)
• Thyroid history/labs if clinically indicated
• Additional labs based on symptoms/comorbidities

Why this matters:

• Baseline values anchor safety and response monitoring.
• Some symptoms during treatment are easier to interpret when baseline abnormalities are known.
• Follow-up thresholds are clearer when starting values are documented.

Domain 3: Medication and supplement interaction review

Bring a complete list including:

• Prescription medications
• OTC medications
• Supplements/herbals
• Dose and timing of each

Focus areas for your prescriber:

• Diabetes regimens that increase hypoglycemia risk when intake drops
• GI-active medications that may amplify symptom burden
• Drugs requiring precise absorption timing if gastric emptying changes

Domain 4: Contraindication and caution screen

Ask directly about high-priority history elements:

• Prior pancreatitis or unexplained severe abdominal pain episodes
• Relevant endocrine tumor history (personal/family) where caution is required
• Significant or progressive GI motility symptoms
• Pregnancy, breastfeeding, or near-term conception plans
• Severe dehydration history, recurrent vomiting syndromes, or frailty concerns

Clinical nuance matters: some findings are hard contraindications; others trigger shared decision-making and closer monitoring.

Domain 5: Behavioral and nutrition readiness

GLP-1 medications support behavior change; they do not replace it.

Core readiness signals:

• Can you maintain hydration targets most days?
• Can you eat protein-forward meals despite appetite suppression?
• Can you follow a bowel-regularity protocol early rather than react late?
• Can you avoid unapproved dose experimentation?

If these are currently unstable, build routine first and start later.

Domain 6: Monitoring logistics and access continuity

Ask yourself:

• Do I have follow-up access within 2–6 weeks after start/titration?
• Can I message my care team if side effects escalate?
• Is my refill pathway reliable?
• Do I understand expected prior-authorization delays?

If access is fragile, start with a continuity plan. For deeper budgeting and interruption planning, review GLP-1 Cost Without Insurance: Real Monthly Scenarios, Prior Authorization Friction, and How to Plan.

Domain 7: Goal specificity and expected timeline

“Lose weight” is understandable but not operationally precise.

Set:

• 1 primary medical target (e.g., glycemic control, blood pressure reduction, mobility function)
• 2 secondary behavioral targets (protein consistency, meal cadence, activity floor)
• 1 safety target (e.g., zero dehydration episodes, constipation prevention protocol adherence)

Specific targets improve treatment pacing and reduce impulsive dose changes.

What to bring to your first GLP-1 appointment (copyable checklist)

Essentials packet

• Photo ID and insurance card (if applicable)
• Full medication/supplement list with doses
• Last 6–12 months of relevant labs/reports
• Blood pressure logs (if available)
• Current weight + recent trend notes
• Symptom history summary (GI symptoms, appetite patterns, sleep, energy)

Questions packet

• What is my main indication for treatment?
• What outcomes define early success for me?
• What side effects should I expect in weeks 1–4?
• What symptoms mean “watch,” “call,” and “urgent care now”?
• What is my titration pace and under what conditions should it pause?
• How will coverage and refill continuity be managed?

Follow-up packet

• Planned follow-up date before leaving the visit
• Preferred communication channel for symptom escalation
• Written instructions for missed dose scenarios
• Written nutrition and hydration priorities for the first month

Who may qualify in typical practice patterns (high-level)

Broadly, clinicians often consider treatment when adults have obesity-range BMI, or overweight-range BMI plus meaningful weight-related comorbidity burden. But context can shift decision quality:

• Two patients with identical BMI may have very different risk profiles.
• Insurer criteria may differ from clinician judgment.
• Access and continuity constraints may influence timing and product selection.

Use BMI criteria as entry points, not final verdicts.

Who may need a “stabilize first, then start” pathway

A temporary stabilization phase can improve tolerance and adherence.

Common triggers:

• Frequent vomiting, significant reflux, or unresolved severe constipation
• High anxiety around eating causing under-fueling and dehydration risk
• Unstable binge-restrict cycles requiring behavioral support first
• Unclear medication reconciliation or missing high-risk history
• Active pregnancy/breastfeeding or planned conception timing conflicts

Stabilization phase goals (often 2–6 weeks):

• Hydration routine established
• Protein intake consistency improved
• Baseline labs and medication interactions clarified
• Symptom plan documented before first dose

This approach often reduces early discontinuation.

Pre-start protocol: the “first 30 days readiness sprint”

Week 0 (before first dose)

• Confirm indication and baseline metrics
• Finalize medication list and timing plan
• Set hydration floor and protein minimum
• Build bowel regularity plan with clinician-approved options
• Schedule first follow-up

Weeks 1–2

• Track nausea, bowel habits, fluid intake, and energy daily
• Keep meals small/structured and protein-prioritized
• Avoid aggressive calorie cuts
• Escalate persistent vomiting, inability to hydrate, or worsening abdominal pain promptly

For a deeper escalation map, see GLP-1 Side Effects Week by Week: What’s Normal, What Needs Escalation.

Weeks 3–4

• Review adherence quality, not just scale changes
• Reassess sleep, movement baseline, and stress load
• Decide with prescriber whether to continue, pause, or adjust pace

If progress stalls after the initial phase, use GLP-1 Weight-Loss Plateau in Months 2–3: Clinical Fixes That Actually Work.

Clinical conversation script (use during your visit)

You can say:

1. “My main treatment goal is ____. My secondary goals are ____ and ____.”
2. “My biggest safety concern is ____. What should my escalation threshold be?”
3. “What daily/weekly metrics do you want me to track?”
4. “Which symptoms are expected adaptation versus concerning progression?”
5. “What is our plan if refill access is delayed?”

A strong visit is less about asking more questions and more about asking higher-quality questions.

Readiness self-check

Bring these basics to your first visit

• Current height, weight, and recent trend
• A complete medication and supplement list
• Relevant recent labs if available
• A clear primary treatment goal
• A short list of questions about risks, monitoring, and follow-up

Ask yourself these readiness questions

• Can I maintain hydration most days?
• Can I prioritize protein-forward meals?
• Can I track symptoms and follow instructions consistently?
• Do I have a reliable follow-up path if symptoms escalate?
• Do I understand that dose changes must be clinician-guided?

Reasons a clinician may recommend waiting before starting

• Severe or unstable GI symptoms
• Incomplete medication reconciliation
• Unclear pregnancy plans
• Unstable follow-up access
• Major uncertainty about hydration, nutrition, or tracking

Common mistakes that delay approval or increase early side effects

1. Arriving with incomplete medication history
2. Treating eligibility as cosmetic-only rather than metabolic risk management
3. Starting without a hydration/constipation protocol
4. Pursuing rapid dose changes based on daily scale fluctuations
5. Ignoring access continuity (coverage, refill timing, pharmacy reliability)

If compounded products are being considered due to access constraints, review safety verification steps in Compounded GLP-1 Safety Checklist: How to Verify Source Quality, Documentation, and Oversight.

Final takeaways

The strongest GLP-1 starts are usually not the fastest starts. They are the most prepared starts:

• Clear indication and baseline data
• Explicit risk and interaction review
• Practical adherence and side-effect protocols
• Realistic access and follow-up planning

If you approach eligibility as a structured clinical process—not a binary gate—you improve both safety and long-term success probability.

Advanced readiness protocol: 5 failure modes and preventive actions

Failure mode 1: Starting with incomplete baseline data

Preventive action:

• Bring at least one objective metabolic marker, blood pressure trend, and 6–12 month weight context.
• If records are fragmented, ask for a baseline consolidation visit before initiation.

Failure mode 2: Treating appetite suppression as a nutrition plan

Preventive action:

• Set minimum protein and hydration targets before first dose.
• Use meal templates to avoid accidental under-fueling.

Failure mode 3: No escalation thresholds in writing

Preventive action:

• Ask your clinic for explicit “monitor vs call vs urgent care” criteria.
• Store instructions where family/support persons can access them.

Failure mode 4: Vague goals causing premature dose pressure

Preventive action:

• Define one clinical outcome and one behavior outcome to review monthly.
• Evaluate trend quality, not daily scale emotion.

Failure mode 5: Access assumptions without contingency planning

Preventive action:

• Clarify refill timelines and prior authorization requirements before initiation.
• Build a communication plan for denials, delays, or source changes.

Pre-visit (7 days before appointment)

• Gather records, medication list, prior weight logs.
• Draft three key questions and one primary treatment goal.
• Log baseline GI symptoms so new symptoms can be contextualized.

Visit day

• Confirm indication, contraindication screen, and monitoring cadence.
• Confirm initial dosing/titration pace and what would trigger pacing changes.
• Confirm insurance and refill workflow owner.

Days 1–30 after start

• Log weekly trend metrics and daily tolerance notes.
• Report persistent hydration/nutrition issues early.
• Reassess readiness behaviors at week 2 and week 4.

If more than one clinician is involved in your care

Bring this brief summary to each visit:

• Your main treatment goal and main risk factors
• Your current dose and titration status
• Any meaningful side-effect trend
• Your current hydration and protein adherence
• Your next follow-up date and pending decisions

FAQ

1) Is BMI the only thing that determines GLP-1 eligibility?

No. BMI is often one entry criterion, but clinicians also assess metabolic risk, comorbidities, medication interactions, contraindications, and follow-up readiness.

2) Can I start GLP-1 treatment if I have GI symptoms already?

Sometimes, but uncontrolled or severe GI symptoms may justify a stabilization-first plan before starting. Your prescriber should individualize timing.

3) What labs should I bring to my first visit?

Common baseline data include glucose markers (A1c/fasting glucose), lipid panel, and general chemistry panels, with additional testing based on your history.

4) What if insurance approval is delayed?

Ask for a documented prior-authorization pathway, expected timelines, and contingency planning before initiating treatment.

5) Is it okay to change my dose if appetite suppression seems weak?

No. Dose and titration changes should be clinician-guided. Self-adjustment can increase side-effect risk and complicate monitoring.

6) Do I need a lifestyle plan if I’m taking a GLP-1?

Yes. Medication response is usually better and safer when paired with protein-forward nutrition, hydration, movement, sleep consistency, and follow-up adherence.